| Literature DB >> 35017401 |
B Vigneshwaran1, Sanjeev Kumar Bhoi2, Mukund Namdev Sable3, Dillip Muduly1, Mahesh Sultania1, Menkha Jha2, Sudipta Mohakud4, Madhabananda Kar1.
Abstract
BACKGROUND: The purpose of this study was to identify the factors which predict the perioperative outcomes after video-assisted thoracoscopic surgery (VATS) thymectomy in patients with myasthenia gravis (MG) or thymic neoplasms. PATIENTS AND METHODS: Data of consecutive patients who had undergone VATS thymectomy in our institution from August 2016 to April 2018 were collected retrospectively from a prospectively maintained database followed by prospective recruitment of patients who underwent VATS thymectomy from April 2018 to February 2020.Entities:
Keywords: Minimally invasive thymectomy; myasthenia gravis; video-assisted thoracoscopic surgery thymectomy; video-assisted thymectomy; videoscopic thymectomy
Year: 2022 PMID: 35017401 PMCID: PMC8830562 DOI: 10.4103/jmas.JMAS_261_20
Source DB: PubMed Journal: J Minim Access Surg ISSN: 1998-3921 Impact factor: 1.407
Baseline characteristics
| Characteristic | |
|---|---|
| Gender | |
| Male | 15 (48.4) |
| Female | 16 (51.6) |
| Age (years), mean±SD | 40.7±14.9 |
| BMI (kg/m2), mean±SD | 23.4±4 |
| Comorbidities | |
| Yes | 12 (38.7) |
| No | 19 (61.2) |
| Indication for VATS thymectomy | |
| Generalized MG | 13 (41.9) |
| Thymoma | 2 (6.4) |
| MG + thymoma | 16 (51.6) |
| Patients with MG | 29/31 (93.5) |
| Duration of MG symptoms (months), median (range) | 6 (1-48) |
| Preoperative disease severity (MGFA class) | |
| Mild (MG II) | 6 (20.7) |
| Moderate (MG III) | 16 (55.2) |
| Severe (MG IV, V) | 7 (24.1) |
| AchRAb positive MG | 27/29 (93.1) |
| Hospital admissions due to MG related issues | |
| Yes | 16 (55.2) |
| No | 13 (44.8) |
| Previous history of myasthenic crisis | 8/29 (27.6) |
| Presence of thymoma | |
| Yes | 18 (58) |
| No | 13 (41.9) |
| Median follow up and range (months) | 14 (2-32) |
SD: Standard deviation, BMI: Body mass index, VATS: Video-assisted thoracoscopic surgery, MG: Myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America
Perioperative outcomes in patients with and without thymoma
| Outcome | Total ( | With thymoma ( | Without thymoma ( |
|
|---|---|---|---|---|
| Operative duration (min) | 196.90±63.53 | 210.22±67.79 | 178.46±54.29 | 0.17 |
| Blood loss (ml) | 122.58±115.35 | 138.89±141 | 100.00±61.23 | 0.36 |
| ICU stay (h) | 32.10±17.27 | 36.50±20.87 | 26.00±7.74 | 0.09 |
| Duration of intubation (min) | 758.55±628.89 | 990.00±639.71 | 438.08±466.25 | 0.01* |
| Hospital stay (days) | 7.97±6.92 | 9.78±8.52 | 5.46±2.29 | 0.08 |
| Major complications‡ | 5 (16.12) | 5 (27.78) | 0 | |
| Postoperative myasthenic crisis | 2 (6.45) | 2 (11.11) | 0 | 0.058 |
| Postoperative weakness causing reintubation | 1 (3.22) | 1 (5.55) | 0 | |
| Phrenic nerve palsy requiring diaphragmatic plication | 1 (3.22) | 1 (5.55) | 0 | |
| Pleural effusion requiring drainage | 1 (3.22) | 1 (5.55) | 0 | |
| Minor complications‡ | 11 (35.48) | 6 () | 5 (38.46) | |
| Post-op weakness requiring noninvasive ventilation | 3 (9.67) | 2 (11.11) | 1 (7.69) | 0.76 |
| Phrenic nerve palsy managed conservatively | 3 (9.67) | 3 (16.67) | 0 | |
| Atrial fibrillation | 1 (3.22) | 0 | 1 (7.69) | |
| Port site infection | 2 (6.45) | 0 | 2 (15.38) | |
| Atelectasis | 1 (3.22) | 1 (5.55) | 0 | |
| Others - postoperative depression | 1 (3.22) | 0 | 1 (7.69) | |
| Phrenic nerve palsy | 4 (12.90) | 4 (22.22) | 0 | 0.12 |
| 30-day mortality | 0 | 0 |
*P<0.05, †Mann-Whitney U-test was used as the test of significance for continuous variables, and Fischer exact test was used for the categorical variables, ‡Major complications are defined as Clavien-Dindo Grade 3, 4 and 5 while Grade 1 and 2 are considered as minor complications
Factors associated with worse perioperative outcomes after video-assisted thoracoscopic surgery thymectomy
| Variable | Hospital stay | Complicationse | |||
|---|---|---|---|---|---|
|
| |||||
|
|
|
|
| ||
| Age | 0.84 | - | <0.05* | 0.49 | 0.34 |
| Gender | 0.17 | 0.32 | 0.23 | - | 0.26† |
| Comorbidity | 0.54 | - | 0.80 | - | 0.87† |
| MGFA class | 0.37 | - | 0.07 | 0.04* | 0.76† |
| MG symptoms >12 months | 0.10 | 0.02* | 0.02* | 0.10 | 0.87† |
| Preoperative myasthenic crisis | 0.15 | 0.78 | 0.82 | - | 0.86 |
| OT duration >3 h | 0.27 | - | 0.48 | 0.44† | |
| Blood loss >100 ml | 0.46 | - | 0.78 | 0.27† | |
| Intubation >24 h | 0.02* | 0.04* | 0.04* | 0.05* | 0.04* |
| ICU stay >48 h | 0.54 | - | 0.82 | - | 0.23† |
| Complications | 0.03* | 0.03* | 0.07 | 0.07 | - |
| Presence of thymoma | 0.08 | 0.34 | 0.02* | 0.73 | 0.46† |
Mann-Whitney U-test was used as the test of significance for continuous variables, and Fischer exact test was used for the categorical variables. *P<0.05; †Fischer exact test. aLinear regression analysis, bMultivariate linear regression analysis (adjusted for factors with P<0.20), cLinear regression analysis (accounting for outliers), dMultivariate linear regression analysis (accounting for outliers) (adjusted for factors with P<0.20), eMultivariate logistic regression analysis. MG: Myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America, ICU: Intensive care unit
Response of myasthenia gravis to thymectomy - DeFilippi classification
| DeFilippi classification | Total ( | With thymoma* ( | Without thymoma ( |
|
|---|---|---|---|---|
| Remission, off medications | 2 (6.9) | 2 (12.5) | 0 | 0.39 |
| Asymptomatic, reduced medications | 15 (51.7) | 6 (37.5) | 9 (69.23) | |
| Improved, on medications | 7 (24.1) | 5 (31.25) | 2 (15.38) | |
| No change | 2 (6.9) | 1 (6.25) | 1 (7.69) | |
| Worse | 1 (3.4) | 1 (6.25) | 0 | |
| Lost to follow up | 2 (6.9) | 1 (6.25) | 1 (7.69) |
*Data of patient who had expired after 1 year included in TG group. TG: Thymoma group
Comparison of outcomes between video-assisted thoracoscopic surgery and transsternal approach for thymectomy
| Variable | VATS approach, | Trans-sternal approach, | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Our study ( | Rowse | Mineo and Ambrogi[ | Xie | Mineo and Ambrogi[ | Kattach | Meyer | |
| Mean operative duration (min) | 196.90±63.53 | 102±39 | 150±35 | 80 | 138±46 | NA | 118.7±27 |
| Mean blood loss (ml) | 122.58±115.35 | 65±41 | 180±39 | 120 | 240±50 | NA | NA |
| Mean hospital stay (days) | 7.97±6.92 | NA | 3.8±1.2 | 9 (5-16) | 4.5±1.7 | 8 (3-75) | 4.6±4.2 |
| Conversion to open | 0 | 0 | 4 (8.5) | 0 | Not applicable | Not applicable | Not applicable |
| Major complications | 5 (16.12) | 7 (16) | 1 (2.1) | 2 (6.5) | 5 (2.5) | 8 (9.4) | NA |
| Complete remission | 2/29 (6.9) | 1/16 (6.3) | 19/47 (40) | 52.10 | 87 (45) | 15 (17) | 15.80 |
| Mean follow up (months) | 14** (2-32) | 18.4 | 149±45 | 42** (25-97) | 149±45 | 54±36 | 72±48 |
**Median follow-up. NA: Data not available